The Quantellect read.As of Nov 19, 2026, 11 active firms cover Solid Biosciences LLC: 11 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $12.00 to $26.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $19.55 sits 208% above the current $6.34. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-1.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy11100%
Neutral00%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$19.55
+208.0% upside
Average target across 11 active firms as of Nov 19, 2026 vs $6.35 current
Highest Target$26.00
Average Target$19.55
Lowest Target$12.00
Detailed analyst forecasts for SLDB
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 11 of 11 active firms rate SLDB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SLDB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.53 – $-0.35 · 8 analysts
Next period, 8 analysts expect Solid Biosciences LLC to earn $-0.41 a share (range $-0.53 – $-0.35), versus — a year earlier. Full-year consensus is $-1.61, growing to $-1.59 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.9M next year.
Top analysts covering Solid Biosciences LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SLDB.
#1
Laura Chico
Wedbush · Rank #55
Buy
$15.00+136.4% to target
Overall win rate
46%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$15.00+136.4% to target
Overall win rate
51%
+ Follow
#3
Luca Issi
RBC Capital · Rank #76
Buy
$18.00+183.7% to target
Overall win rate
49%
+ Follow
#4
Geulah Livshits
Chardan Capital · Rank #104
Buy
$15.00+136.4% to target
Overall win rate
43%
+ Follow
#5
Anupam Rama
JP Morgan · Rank #171
Buy
No targeton SLDB
Overall win rate
48%
+ Follow
SLDB stock forecast FAQ
What is SLDB's average 12-month price target?+
The 11 active firms with a live target average $19.55 for Solid Biosciences LLC over the next 12 months, ranging from a $26.00 high to a $12.00 low, as of Nov 19, 2026.
Is SLDB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SLDB?+
The Street-high target is $26.00 (Cantor Fitzgerald), and the Street-low is $12.00 (JP Morgan). The average of all 11 active-firm targets is $19.55.
How many active Wall Street firms cover SLDB?+
11 active firms have a recognized rating on Solid Biosciences LLC as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SLDB?+
Among analysts who currently cover SLDB, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $15.00 target.
What is Solid Biosciences LLC's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.53 – $-0.35) across 8 analysts. Full-year EPS is projected at $-1.61, rising to $-1.59 the following year.
How much revenue is Solid Biosciences LLC expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.9M next year.
Have analysts been upgrading or downgrading SLDB lately?+
As of Nov 19, 2026, 11 of 11 active firms rate SLDB a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SLDB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.